LIXTE BIOTECHNOLOGY HOLDINGS, INC.

LIXT · Nasdaq · SIC 2834: Pharmaceutical Preparations
239
SEC Filings

Business Summary

LIXTE Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical and proton cancer therapy company. Its primary asset is LB-100, a small molecule inhibitor of protein phosphatase 2A (PP2A) being tested in clinical trials for ovarian clear cell carcinoma, metastatic MSS colon cancer, and advanced soft tissue sarcoma. The company is also the majority shareholder of Liora Technologies Europe Ltd., which is developing the LiGHT System, an electronically controlled proton therapy system for treating tumors.

Next Earnings

Q2 FY2026 — expected 2026-09-11

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionLIXTdiscussed_in_filing Cybersecurity
topic_mentionLIXTdiscussed_in_filing Trusted Computing
topic_mentionLIXTdiscussed_in_filing Blockchain & Crypto
topic_mentionLIXTdiscussed_in_filing Regulation
topic_mentionLIXTdiscussed_in_filing Healthcare & Bio
topic_mentionLIXTdiscussed_in_filing Cybersecurity
topic_mentionLIXTdiscussed_in_filing Trusted Computing
topic_mentionLIXTdiscussed_in_filing Blockchain & Crypto
topic_mentionLIXTdiscussed_in_filing Regulation
topic_mentionLIXTdiscussed_in_filing Healthcare & Bio
topic_mentionLIXTdiscussed_in_filing Cybersecurity
topic_mentionLIXTdiscussed_in_filing Trusted Computing
topic_mentionLIXTdiscussed_in_filing Blockchain & Crypto
topic_mentionLIXTdiscussed_in_filing Regulation
topic_mentionLIXTdiscussed_in_filing Healthcare & Bio
topic_mentionLIXTdiscussed_in_filing Cybersecurity
topic_mentionLIXTdiscussed_in_filing Trusted Computing
topic_mentionLIXTdiscussed_in_filing Blockchain & Crypto
topic_mentionLIXTdiscussed_in_filing Regulation
topic_mentionLIXTdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-312025-12-310001493152-26-014052EDGAR97K words
2025-03-242024-12-310001641172-25-000208EDGAR—
2024-03-192023-12-310001493152-24-010427EDGAR—
2023-03-292022-12-310001493152-23-009386EDGAR—
2022-03-212021-12-310001493152-22-007327EDGAR—
2021-03-262020-12-310001493152-21-006882EDGAR—
2020-03-252019-12-310001493152-20-004697EDGAR—
2019-03-252018-12-310001493152-19-003870EDGAR—
2018-03-232017-12-310001493152-18-003806EDGAR—
2017-03-292016-12-310001493152-17-002940EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-122025-09-300001493152-25-021941EDGAR50K words
2025-08-072025-06-300001641172-25-022517EDGAR—
2025-05-122025-03-310001641172-25-009575EDGAR—
2024-11-122024-09-300001493152-24-044810EDGAR—
2024-08-082024-06-300001493152-24-030757EDGAR—
2024-05-092024-03-310001493152-24-018337EDGAR—
2023-11-092023-09-300001493152-23-040115EDGAR—
2023-08-092023-06-300001493152-23-027269EDGAR—
2023-05-102023-03-310001493152-23-016069EDGAR—
2022-11-082022-09-300001493152-22-030878EDGAR—
2022-08-102022-06-300001493152-22-021832EDGAR—
2022-05-112022-03-310001493152-22-012779EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-200001493152-26-011829EDGAR1K words
2026-03-100001493152-26-009526EDGAR—
2026-02-180001493152-26-007268EDGAR—
2025-12-310001493152-25-029778EDGAR—
2025-12-230001493152-25-028999EDGAR—
2025-12-220001493152-25-028850EDGAR—
2025-12-110001493152-25-027219EDGAR—
2025-11-250001493152-25-024996EDGAR—
2025-09-110001641172-25-027109EDGAR—
2025-09-040001641172-25-026448EDGAR—

239 total filings indexed. 207 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

oncology cancer-immunotherapy proton-cancer-therapy clinical-stage-biopharmaceuticals

Company Identity

CIK0001335105
TickerLIXT
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: cf0d3062840b6e9ce18fd5e8629535719b8de2fe84450ed9f869f9997877bd67
parent: e8f53b2e43cb9fa25225209b73d698952aca14bcadfcb0b12af17c35babd5698
content hash: cd6f783e845e4fee11bad09ecdb78b124dc8704e826c15b62156ae977da8ed36
signed: 2026-04-13T04:46:03.292Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf